Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai to File Antibody Cocktail for COVID-19 Prevention among Close Contact Individuals
August 27, 2021
- Wakamoto Kicks Off MaQaid PIII Study in China, Eyes Launch in FY2023
August 27, 2021
- Rakuten Medical Eyes Label Expansion for Photoimmunotherapy, Asia as Key Market
August 26, 2021
- ASKA to Accelerate Innovative Pharma Biz, Not Generics; President Sees Trivial Impact from Follow-On Blopress AG
August 25, 2021
- All Ranitidine Products to Be Discontinued in Japan as Nipro to End Injection Sales
August 25, 2021
- Nipro to Develop AI System to Predict Severe COVID-19
August 25, 2021
- Meiji’s PDE4 Inhibitor Delivers in PI; PII Psoriasis Trial Slated to Begin Next Year
August 25, 2021
- All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
August 25, 2021
- Drug Makers’ Q1 Operating Profits Eclipsing Projections on One-Time Gains, Product Growth
August 24, 2021
- DS Espha to Launch Velcade Authorized Generic in December
August 24, 2021
- Bayer Yakuhin Names Julio Triana as New President
August 23, 2021
- HIF-PH Drug Evrenzo Gets European Nod: Astellas/FibroGen
August 23, 2021
- Ono’s Colorectal Cancer Drug Braftovi Approved in South Korea
August 23, 2021
- Shipments of 64 Choseido-Made Products Now Adjusted or Halted
August 20, 2021
- Sawai’s Shipment Curbs Now Affect 414 Products
August 20, 2021
- Sanwa Kagaku Rolls Out Upasita for Secondary Hyperparathyroidism
August 20, 2021
- Nihon Generic Lifts Shipment Curbs on Symbicort Generic
August 19, 2021
- MEI, Kyowa Begin PIII Study on Lymphoma Drug Zandelisib
August 19, 2021
- Rexulti Misses Mark in PII BPD Trial: Otsuka
August 19, 2021
- Yamasa Ramps Up API CMO Biz for Oligonucleotides, mRNA Drugs amid Changes in Modalities
August 19, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…